Optimal cytoreduction

The Role of HE4, a Novel Biomarker, in Predicting Optimal Cytoreduction After Neoadjuvant Chemotherapy in Advanced Ovarian Cancer
Francesco Plotti, Giuseppe Scaletta, Stella Capriglione, Roberto Montera, Daniela Luvero, Salvatore Lopez, Alessandra Gatti, Carlo De Cicco Nardone, Corrado Terranova, Roberto Angioli

International Journal of Gynecologic Cancer May 2017, 27 (4) 696-702; DOI: 10.1097/IGC.0000000000000944
Prognostic Value of Residual Tumor Size in Patients With Epithelial Ovarian Cancer FIGO Stages IIA–IV: Analysis of the OVCAD Data
Stephan Polterauer, Ignace Vergote, Nicole Concin, Ioana Braicu, Radoslav Chekerov, Sven Mahner, Linn Woelber, Isabelle Cadron, Toon Van Gorp, Robert Zeillinger, Dan Cacsire Castillo-Tong, Jalid Sehouli

International Journal of Gynecologic Cancer Mar 2012, 22 (3) 380-385; DOI: 10.1097/IGC.0b013e31823de6ae
Outcomes for patients with fallopian tube carcinoma managed with adjuvant chemotherapy following primary surgery: a retrospective university experience
C. A. Leath, T. M. Numnum, J. M. Straughn, R. P. Rocconi, W. K. Huh, L. C. Kilgore, E. E. Partridge

International Journal of Gynecologic Cancer Sep 2007, 17 (5) 998-1002; DOI: 10.1111/j.1525-1438.2007.00903.x
CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer
S. Memarzadeh, S. B. Lee, J. S. Berek, R. Farias-Eisner

International Journal of Gynecologic Cancer Feb 2003, 13 (2) 120-124; DOI: 10.1136/ijgc-00009577-200303000-00003

Log in using your username and password

Main menu

Log in using your username and password

You are here

Optimal cytoreduction